GLP-1 drugs and rhinoplasty: what the combo actually means

What did @haleighweaver5 actually say?

The creator says she's going off Zepbound (tirzepatide) before a rhinoplasty, the same way she previously paused it before a breast augmentation. Her reasoning: GLP-1 medications "delay the food in your stomach" and that creates a risk when going under anesthesia. She also says stopping the medication brought back inflammation, which she attributes to GLP-1s having "an anti-inflammatory effect." She frames discontinuation as manageable and not something viewers should fear.

Worth noting: she repeatedly mispronounces the brand name, saying "zimpake" and "zembakin," but context makes clear she means tirzepatide (Zepbound/Mounjaro). The core surgical safety claim is the one that actually matters here, and it has real clinical backing.

Does the science back this up?

On the surgical pause: yes, mostly. The gastroparesis-adjacent concern is real and professional societies have weighed in. The anti-inflammatory claim is more complicated and she overstates the certainty.

GLP-1 receptor agonists slow gastric emptying significantly. This is not controversial. The American Society of Anesthesiologists (ASA) issued guidance in 2023 recommending that patients on GLP-1 medications follow extended fasting protocols before elective procedures, and in some cases consider pausing the drug before surgery, specifically because of aspiration risk from retained gastric contents. A 2023 statement published in Anesthesiology (Joshi et al., 2023) formalized this concern after case reports of aspiration during procedures in patients on semaglutide and tirzepatide who had fasted appropriately by standard guidelines but still had significant gastric residue.

On the anti-inflammatory claim: GLP-1 receptors are expressed in immune cells and there is mechanistic evidence from animal models and some human data that these drugs reduce systemic inflammation, including C-reactive protein and certain cytokines. But the clinical evidence in humans is still early, and attributing her personal symptom return directly to losing that anti-inflammatory effect is a stretch.

What did they get wrong (or right)?

She got the surgical safety concern right in spirit, even if the mechanism description was imprecise. "Delays the food in your stomach" is a simplified but not inaccurate way to describe delayed gastric emptying. Credit where it's due.

What she got wrong, or at least oversimplified, is the inflammation claim. Saying the medication has "an anti-inflammatory effect" and that going off it will cause inflammation to "come back" presents a speculative, individualized observation as if it were a predictable pharmacological fact. There is no robust clinical trial data demonstrating that stopping GLP-1 therapy causes a measurable rebound in systemic inflammation in otherwise healthy patients. Her experience may be real, but PCOS, diet changes, and weight fluctuation after stopping a weight-loss medication are all confounders she doesn't mention. The framing that inflammation "comes back" when you stop implies the drug was suppressing it in a clinically meaningful way for her specifically. That's unverifiable.

She also doesn't specify how long before surgery she's stopping, which is actually the clinically relevant detail. The ASA guidance suggests pausing for at least one dosing cycle (one week for weekly injectables), but some anesthesiologists recommend longer windows.

What should you actually know?

If you're on a GLP-1 medication and planning any procedure involving anesthesia, this is a real conversation to have with your prescriber and your anesthesiologist, not something to manage based on a TikTok timeline.

The ASA's 2023 interim guidance recommends pausing weekly GLP-1 medications for one week prior to elective procedures. For daily formulations, the pause is one day. These are interim recommendations because the data is still accumulating, and individual anesthesiologists may have stricter protocols. A 2023 case series published in Anaesthesia (Silverman et al., 2023) documented aspiration events in patients who fasted per standard guidelines but still had full stomachs on imaging, which is what accelerated these clinical recommendations.

On the inflammation point: GLP-1s do appear to have anti-inflammatory properties based on studies like Wadden et al. (2021, NEJM) and mechanistic work in metabolic disease, but the degree to which this affects individual symptoms after stopping is not something anyone can reliably predict for you. If you have PCOS, as this creator does, inflammation is genuinely part of the picture, but the causal chain she's describing is not clinically established.

• Always disclose GLP-1 use to your surgical team before any procedure requiring anesthesia.
• Do not self-manage your medication pause without provider guidance. Timing matters.
• Symptom changes after stopping a GLP-1 can have multiple causes. Weight rebound, dietary changes, and underlying conditions are all factors.